Atelvia

Base Information

• Chemical Name: Atelvia
• CAS No.: 115436-72-1
• Molecular Formula: C7H10NNaO7P2
• Molecular Weight: 350.13
• Hs Code.: 29333990
• DSSTox Substance ID: DTXSID1046132
• ChEMBL ID: CHEMBL3560765
• Mol file: 115436-72-1.mol

Synonyms:DTXSID1046132;Actonel;Atelvia;DTXCID9026132;C7-H10-N-O7-P2.Na;CAS-115436-72-1;NCGC00160405-01;CHEMBL3560765;Tox21_111791;Tox21_111791_1;NCGC00274056-01;A803434;disodium hydroxy-[1-hydroxy-1-[hydroxy(oxido)phosphoryl]-2-(3-pyridinyl)ethyl]phosphinate;disodium [1-[oxidanidyl(oxidanyl)phosphoryl]-1-oxidanyl-2-pyridin-3-yl-ethyl]-oxidanyl-phosphinate

Chemical Property of Atelvia

Chemical Property:

• Appearance/Colour: fine white to off-white crystalline powder
• Vapor Pressure: 4.03E-20mmHg at 25°C
• Melting Point: 252-262°C
• Boiling Point: 692.3 °C at 760 mmHg
• Flash Point: 372.5 °C
• PSA: 170.63000
• LogP: 0.06380
• Storage Temp.: Store at RT
• Solubility.: H2O: soluble5mg/mL, clear (warmed)
• Hydrogen Bond Donor Count: 3
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 4
• Exact Mass: 326.96496419
• Heavy Atom Count: 19
• Complexity: 335

Purity/Quality:

99% ^*data from raw suppliers

Risedronic Acid, Sodium Salt ^*data from reagent suppliers

Safty Information:

• Statements: 62-64
• Safety Statements: 20-22-36/37

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1=CC(=CN=C1)CC(O)(P(=O)(O)[O-])P(=O)(O)[O-].[Na+].[Na+]
• Recent ClinicalTrials: A Study of Actonel for the Prevention of Bone Loss
• Recent EU Clinical Trials: Teriparatide and Risedronate in the Treatment of Patients with Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures
• Description: Risedronate sodium is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Risedronate sodium is used for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures, treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures, treatment of osteoporosis in men at high risk of fractures, and treatment of Paget’s disease. It is marketed as Actonel (tablet) and Atelvia (delayed-release tablet). Risedronate sodium was launched as Actonel in the US for treatment of Paget's disease. Risedronic acid is readily obtained by condensation of 2-(3- pyridyl)acetic acid with phosphorous acid in presence of phosphorus oxychloride. Risedronate sodium is an orally active bisphosphonate of third generation, showing more potent bone antiresorptive properties than most of prior bisphosphonates like etidronate which has been used for the same indication since 1978. The biological mechanism by which Risedronate, and generally bisphosphonates, act is not quite clear presently ; recent advances have suggested that aminobisphosphonates interfere with the HMG-CoA pathway and inhibit protein prenylation, causing apoptosis of osteoclasts and macrophages. These apoptotic effects are correlated to the anti-resorptive properties of this class of compounds. In a 2 month clinical trial involving patients with Paget's desease, 30 mg risedronate daily achieved an appreciable reduction of serum alkaline phosphatase levels, an indicator of bone stabilization, in 77% of patients, compared with 11% on etidronate at 400 mg daily for 6 months. Risedronate is also in development for the treatment and prevention of various bone diseases, particularly post-menopausal and corticosteroid-induced osteoporosis.
• Uses: antibacterial Osteoporosis
• Clinical Use: Bisphosphonate: Treatment and prevention of osteoporosis (including corticosteroid induced) Paget’s disease
• Drug interactions: Potentially hazardous interactions with other drugs Calcium-containing substances: avoid for 2 hours before and after administration.